XNASMMSI
Market cap5.72bUSD
Jan 08, Last price
98.14USD
1D
2.38%
1Q
4.67%
Jan 2017
270.34%
Name
Merit Medical Systems Inc
Chart & Performance
Profile
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,257,366 9.24% | 1,150,981 7.09% | |||||||
Cost of revenue | 756,222 | 707,392 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 501,144 | 443,589 | |||||||
NOPBT Margin | 39.86% | 38.54% | |||||||
Operating Taxes | 17,678 | 8,113 | |||||||
Tax Rate | 3.53% | 1.83% | |||||||
NOPAT | 483,466 | 435,476 | |||||||
Net income | 94,411 26.70% | 74,516 53.79% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 15,584 | 17,596 | |||||||
BB yield | -0.35% | -0.43% | |||||||
Debt | |||||||||
Debt current | 12,087 | 22,255 | |||||||
Long-term debt | 947,618 | 317,236 | |||||||
Deferred revenue | 1,605 | 1,708 | |||||||
Other long-term liabilities | 33,256 | 32,259 | |||||||
Net debt | 351,508 | 265,507 | |||||||
Cash flow | |||||||||
Cash from operating activities | 145,151 | 114,291 | |||||||
CAPEX | (36,701) | (45,029) | |||||||
Cash from investing activities | (175,347) | (57,397) | |||||||
Cash from financing activities | 559,266 | (60,260) | |||||||
FCF | 420,564 | 350,174 | |||||||
Balance | |||||||||
Cash | 589,136 | 58,408 | |||||||
Long term investments | 19,061 | 15,576 | |||||||
Excess cash | 545,329 | 16,435 | |||||||
Stockholders' equity | 1,202,000 | 1,144,397 | |||||||
Invested Capital | 1,582,891 | 1,423,982 | |||||||
ROIC | 32.16% | 31.19% | |||||||
ROCE | 23.49% | 30.41% | |||||||
EV | |||||||||
Common stock shares outstanding | 58,356 | 57,671 | |||||||
Price | 75.96 7.56% | 70.62 13.35% | |||||||
Market cap | 4,432,722 8.84% | 4,072,726 13.97% | |||||||
EV | 4,784,230 | 4,338,233 | |||||||
EBITDA | 602,436 | 535,787 | |||||||
EV/EBITDA | 7.94 | 8.10 | |||||||
Interest | 15,511 | 6,339 | |||||||
Interest/NOPBT | 3.10% | 1.43% |